Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study

Date

21 Oct 2023

Session

Poster session 11

Topics

COVID-19 and Cancer

Tumour Site

Colon and Rectal Cancer

Presenters

Alessandro Parisi

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

A. Parisi1, F. Gelsomino2, D. Traisci3, F. Barbin4, L. Salvatore5, F.R. di pietro6, F. Zoratto7, A. Lanese8, S. villani1, A. magnarini1, A. Spallanzani9, N. D'Ostilio3, M. Bensi5, F. Schietroma5, R. Bisonni8, M.B.L. Rocchi10, R. Giampieri1, G. Mentrasti11, R. Berardi12

Author affiliations

  • 1 Clinica Di Oncologia, AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, 60126 - Torrette di Ancona/IT
  • 2 Oncology Department, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 3 Ospedale San Pio Da Pietralcina, ASL Lanciano Vasto Chieti, 66054 - Vasto/IT
  • 4 Medical Oncology Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano/IT
  • 5 Dipartimento Di Oncologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 - Rome/IT
  • 6 Viale Augusto 9,, IDI - Istituto dermopatico dell'immacolata - IRCCS, 00167 - Rome/IT
  • 7 Oncology Unit, Ospedale Santa Maria Goretti - ASL Latina, 04100 - Latina/IT
  • 8 Oncology Department, ASUR MARCHE Area Vasta 4, 63900 - Fermo/IT
  • 9 Dipartimento Di Oncologia, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 10 Department Of Biomolecular Science, Università degli Studi di Urbino, 61121 - Urbino/IT
  • 11 Oncology Clinic Department, AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, 60126 - Torrette di Ancona/IT
  • 12 Clinical Oncology, Dept. Of Internal Medicine, AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, 60126 - Torrette di Ancona/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 648P

Background

As extended analysis of the COVID-DELAY study, we aimed to assess COVID-19 impact on diagnosis, staging and treatment outcomes of CRC patients in 2021 and 2022 compared to 2019 and 2020.

Methods

All consecutive newly diagnosed CRC patients referred to 8 Italian Oncology Departments between March and December 2019, 2020, 2021, and 2022 were evaluated. Access rate (number of patients/year), demographic characteristics, diagnostic and therapeutic temporal intervals (between date of symptoms onset, radiological and cytohistological diagnosis, treatment start, and first radiological evaluation), as well as PFS and OS were assessed and compared.

Results

Compared to 2019 (n=485), a reduction in new CRC cases was found in 2020 (n=390, -19.6%). On the other hand, a progressive increase in new CRC diagnosis was found in 2021 (n= 461, +18.2%) and 2022 (n= 509, +30.5%), compared to 2020. A higher rate of stage IV tumours was diagnosed in 2020 (31.3%) and 2021 (29.6%) compared to 2019 (20.8%), with a normalization in 2022 (22.8%) (p<0.001); a lower number of patients has been discussed in multidisciplinary tumor boards in 2020 (22.1%) compared to 2019 (34.9%), 2021 (37.0%), and 2022 (47.6%) (p<0.001). A significant difference in terms of temporal interval between histological diagnosis and first oncological examination (median of 31 vs. 38 days, respectively, p=0.004), cytohistological diagnosis and systemic treatment start (median of 52 vs. 58 day, p<0.001), first oncological appointment and systemic treatment start (median of 52 compared to 58 days, p=0.034), was found between 2020 and 2021-2022 years, respectively. At multivariate analysis, the 2021-2022 years confirmed to be associated with a reduction in the risk of disease progression compared to 2020 (HR=0.71 (0.53-0-97); p=0.031).

Conclusions

A worsening drop in CRC diagnosis in 2020, with a progressive increase in 2021 and 2022, in parallel with a higher incidence of late-stage CRC diagnosed in 2020 and 2021. This might have affected some diagnostic-therapeutic time intervals in 2021-2022 years compared to 2020.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.